Retatrutide

Evidence record

Product and route

Studied as a subcutaneous injection.

Approval scope

Investigational; no FDA-approved product.

Mechanism

Activates GIP, GLP-1 and glucagon receptors.

Evidence

A randomized obesity trial was funded by Lilly.

Limits

Trial averages do not predict an individual outcome.

Safety context

The trial reported gastrointestinal adverse events.

A reading exercise

For a page discussing retatrutide, make a before and after list of research questions. Use before for questions documented in the study plan and after for questions introduced while examining results. If the available records do not establish when a question was chosen, write timing unclear. This exercise is about tracing a question's history, not dismissing an interesting finding. Pick the page's main conclusion and find where its underlying question appears on your list. Then ask whether the wording tells readers which kind of question it answers, and what a separate study could check next.

Questions to take away

1. Where was the question behind the page's main conclusion first documented?
2. Can you establish when that question was chosen from the available records?
3. What would a separate study need to specify before checking the same idea?